Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin and Isotretinoin in High-Risk Medulloblastoma/PNET
NCT00392327Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- May 2007
- Primary completion
- Jun 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of carboplatin and isotretinoin in medulloblastoma and primitive neuroectodermal tumor (PNET) (4 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free Survival at 5 years. Started May 2007; status: completed.
02
Drugs
carboplatinisotretinoin
03
Conditions
medulloblastomaprimitive neuroectodermal tumor (PNET)
Beyond the preview
Go deeper on NCT00392327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392327.